<DOC>
	<DOCNO>NCT00982436</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety neoadjuvant chemotherapy ( chemotherapy give radiotherapy ) use cisplatin docetaxel , follow carboplatin give time radiotherapy treatment locally advanced head neck cancer .</brief_summary>
	<brief_title>Neoadjuvant Cisplatin/Docetaxel ( CDDP/TXT ) Chemoradiation Head Neck Cancer</brief_title>
	<detailed_description>Chemoradiotherapy become standard care patient unresectable head neck cancer , substantial add toxicity chemoradiotherapy compare radiation therapy alone . Neoadjuvant therapy cisplatin / 5-fluorouracil demonstrate activity disease , taxanes appear improve response . Docetaxel / cisplatin / 5-fluorouracil show highly active regimen . However , potential add toxicity neoadjuvant chemotherapy , important minimize toxicity maintain efficacy . Chemotherapeutic agent DNA cycle-specific like 5-fluorouracil stomatotoxic cell phase non-specific . Of note , several study suggest docetaxel cisplatin highly active combination use advanced disease neoadjuvant therapy . This study therefore test efficacy neoadjuvant chemotherapy cisplatin docetaxel without 5-fluorouracil follow chemoradiotherapy carboplatin determine whether promising response rate modest toxicity achieve . Carboplatin use radiosensitizing agent chemoradiotherapy reduce nephrotoxicity neurotoxicity compare treatment cisplatin .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically proven locoregional Stage 4 squamous cell carcinoma oral cavity , larynx , oropharynx hypopharynx Measurable evaluable disease No distant metastases Tumor surgically unresectable cure resection consider inadvisable Age &gt; 18 year ECOG performance status 0 , 1 2 Life expectancy &gt; 2 month Patients must adequate organ marrow function define : Leukocytes &gt; 3,000/mm3 Absolute neutrophil count &gt; 1,500/mm3 Platelets &gt; 100,000/mm3 Hemoglobin &gt; 10.0g/dL Total Bilirubin &lt; = institutional upper limit normal Aspartate aminotransferase &lt; 2.5 X institutional upper limit normal Alanine aminotransferase &lt; 2.5 X institutional upper limit normal Alkaline phosphatase &lt; 2.5 X institutional upper limit normal Creatinine &lt; = institutional upper limit normal OR creatinine clearance &gt; 60 mL/min/1.73 m2 patient creatinine &gt; institutional upper limit normal Signed inform consent Women childbearing potential men must willing able practice adequate contraception prior study entry duration study treatment Previous chemotherapy malignancy Previous radiotherapy head neck region Other malignancy within last 5 year except nonmelanoma skin cancer Uncontrolled intercurrent illness would prevent delivery protocol therapy Peripheral neuropathy &gt; Grade 2 Hypercalcemia Patient pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Combined Modality Therapy</keyword>
	<keyword>Neoadjuvant Therapy</keyword>
	<keyword>Head neck neoplasm</keyword>
</DOC>